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Summal~ 
There is considerable  interest in designing an effective vaccine to the ubiquitous Epstein-Barr 
virus (EBV). An important role for EBV-specific  cytotoxic T lymphocytes (CTLs) in eliminating 
virus-infected cells is well established. Limited studies using a small number of immune donors 
have defined target epitopes within the latent antigens of EBV. The present study provides an 
extensive analysis of the distribution of class I-restricted CTL epitopes within EBV-encoded  proteins. 
Using recombinant vaccinia encoding individual EBV latent antigens (Epstein-Barr nuclear antigen 
[EBNA] 1, 2, 3A, 3B, 3C, LP, and LMP 1), we have successfully  localized target epitopes recognized 
by CTL clones from a panel of 14 EBV-immune donors. Of the 20 CTL epitopes localized, 
five were defined at the peptide level. Although CTL clones specific for nine epitopes recognized 
both type I and type 2 transformants, a significant number of epitopes (7/16 epitopes for which 
EBV type specificity was determined) were detected only on type 1 EBV transformants. Vaccinia 
recombinants encoding EBNA 3A and EBNA 3C were recognized more frequently than any 
other vaccinia recombinants used in this study, while no CTL epitopes were localized in EBNA 
1. Surprisingly, epitope specificity for a large number of EBV-specific CTL clones could not be 
localized, although vaccinia recombinants used in this study encoded most of the latent antigens 
of EBV. These results suggest that any EBV vaccine based on CTL epitopes designed to provide 
widespread protection will need to include not only latent antigen sequences but also other regions 
of the genome. The apparent inability of human CTLs to recognize EBNA I as a target antigen, 
often the only latent antigen expressed in Burkitt's lymphoma and nasopharyngeal carcinoma, 
suggests that EBV-specific CTL control of these tumors will not be feasible unless the down- 
regulation of latent antigens can be reversed. 
p rotective immunity to viral infection requires the devel- 
opment of memory T cells that recognize viral antigens 
in association with class I MHC. Earlier studies on influenza 
virus first highlighted the important role of CD8 + CTLs, 
which recognize virus-encoded proteins in the form of short 
peptides (1). Since it is well established  that immunization 
with whole viral proteins is unable to elicit an efficient CTL 
response, interest has been directed towards peptide vaccines 
based on defined epitope sequences. This is particularly the 
case with oncogenic viruses, since individual viral genes in- 
troduced in recombinant vectors have the potential to ini- 
tiate tumorigenic processes. Thus, it is important to deter- 
mine the distribution of these epitopes within viral proteins 
and the frequency with which infected cells from a significant 
cohort of immune donors present these epitopes in associa- 
tion with MHC class I alleles. Because of the potential im- 
portance of CTL epitopes in the future development of a vac- 
cine to EBV, a herpes virus with known oncogenic potential, 
there is considerable interest in defining these EBV-encoded 
molecules recognized by CTLs. 
EBV is the etiological agent of infectious mononucleosis 
(IM) 1 and  is  associated  with  Burkitt's  lymphoma (BL), 
nasopharyngeal carcinoma (NPC)  (2),  lymphomas in im- 
munocompromised  individuals (3), and more recent evidence 
suggests an association with Hodgkin's lymphoma (4). Two 
1 Abbreviations used in this paper: BL, Burkitt's lymphoma; EBNA, Epstein- 
Barr nuclear antigen; IM, infectious mononucleosis;  LCL, lymphoblastoid 
cell line; LMP, latent  membrane protein; LP,  leader protein;  NPC, 
nasopharyngeal carcinoma; TP,  terminal protein; UM,  unfractionated 
mononuclear, 
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nized that show DNA sequence divergence within the BamHI 
WYH and E regions of the genome (5-7). In vitro, the virus 
transforms  human  B  cells  into  lymphoblastoid  cell  lines 
(LCLs), which express a limited number of viral gene prod- 
ucts,  including  a  family  of Epstein-Barr  nuclear  antigens 
(EBNA): 1, 2, 3A, 3B, and 3C, leader protein (EBNA LP), 
latent membrane proteins (LMP 1 and 2), and terminal pro- 
teins (TP 1 and 2) (5). An alternative nomenclature also in 
current use designates the EBNA family as EBNA 1, 2, 3, 
4, and 6, and EBNA-5/LP (4, 5). In contrast, latent antigen 
expression in BL and NPC is restricted to EBNA 1 (in some 
instances  LMP is also expressed in NPC)  (8). 
In all previously infected individuals, the virus persists for 
life as a latent infection in B cells and is apparently restrained 
by a population of EBV-specific CTLs (9, 10). This CTL re- 
sponse is a classic virus-specific response (CDS,  class  I re- 
stricted) (10), though CD4 class II-restricted cells have also 
been described (9). The key observation in defining the first 
peptide epitope recognized by EBV-specific  CTLs was that 
in certain donors it was possible to exploit the alMic poly- 
morphism in the EBNA proteins between type 1 and type 
2 EBV by isolating type 1-specific CTL clones (11). These 
clones provided an opportunity to screen selected EBNA pep- 
tides for reactivity on type 2 transformants.  This led to the 
definition of an EBV-speeific CTL epitope that was present 
on type 1 but not type 2 transformants (12).  A second epi- 
tope, derived from EBNA 3C and present on both type 1 
and type 2 transformants, has also been described (13). While 
this approach was very successful in defining a limited number 
of CTL epitopes, their overall  distribution within EBV la- 
tent  antigens  was largely undetermined. 
Two recent technical advances from our laboratories have 
facilitated this study. First, the construction of recombinant 
vaccinia capable of expressing individual EBV latent antigens, 
and second, the establishment of an EBV-negative host cell 
(anti-/, B cell blasts) for these recombinant vaccinia (14, 15). 
In the present report, we have localized EBV CTL epitopes 
recognized by multiple CTL clones from a panel of immune 
donors to generate the first comprehensive analysis of the dis- 
tribution of CTL epitopes within the EBV latent antigens. 
This approach was combined with peptide epitope mapping, 
which permitted the identification of a number of new CTL 
epitopes. Moreover, since EBV infection is associated with 
BL and NPC, another important objective of this study was 
to determine whether any CTL epitopes are localized within 
EBNA  1 and/or  LMP. 
Materials  and Methods 
Establishment and Maintenance ~ EBV'transf~  Cell Lines"  LCLs 
were established from a panel of healthy EBV-seropositive  donors 
listed in Table 1 by exogenous virus transformation  of peripheral 
B cells using type 1 (B95.8 and IARC-BL74) or type 2 (Ag876) 
EBV isolates (11), and were routinely maintained in RPMI 1640 
containing 2 mM glutamine, 100 IU/mlpenicillin, and 100/~g/ml 
streptomycin plus 10% FCS (growth medium). LCLs were desig- 
hated with the donors initial followed by the transforming  virus 
source (e.g., LC/B95.8 designates B lymphocytes from donor LC 
transformed  with virus from the B95.8 cell line). 
Generation of  Anti-~u B CelI Blasts.  Unfractionated mononuclear 
(UM) cells were separated on Ficoll/Paque (Pharmacia, Uppsala, 
Sweden) and depleted of T cells using E-rosetting  (16). The en- 
riched B lymphocytes were cultured in growth medium containing 
anti-IgM (/~ chain specific) coupled to acrylamide beads (Bio-Rad 
Laboratories, Richmond, CA), human riD4 (50 U/ml; Genzyme, 
Boston,  MA), and highly purified human  rlL-2 from Escherichia 
coli (20-40 U/ml) (17, 18). After 48-72 h, B cell blasts were sus- 
pended in growth medium supplemented with rib2 (20-40 U/ml). 
The B cells continue  to divide two to three times/wk for 3 wk 
in the presence of rlL-2. These cells are referred to as anti-# B cell 
blasts. 
Vaccinia Virus Recomln'nants.  Recombinant  vaccinia constructs 
for different EBNA genes have been previously described (14, 15, 
19). All EBV sequences were derived from the B95.8 strain of virus. 
The EBNA 3A sequence was derived from the eDNA Clone T216 
(7), which consists of the 5' portion of the EBNA 3A coding se- 
quence, crossing the splice site and extending  to the EcoRI site 
located at position 93166. This plasmid was digested with PstI and 
colhpsed onto itself to remove 5' noncoding sequences. The resulting 
plasmid, T216P, was opened at the EcoRI site and ligated to the 
genomic EcoK fragment derived from plasmid PMH36, recreating 
the intact full-length EBNA 3A coding sequence. The EBNA 3A 
coding region was excised  with PstI and EcoRV and ligated to Psc11 
at the Sinai site. The EBNA 3B was derived from the eDNA clone 
PMLFT7. The portion of the open reading frame crossing the splice 
junction was excised with SpeI and XbaI and inserted into SpeI- 
digested pBluescript. The resulting plasmid was digested with SpeI 
and EcoRI and ligated to a 440-bp genomic fragment from EcoRI 
(95243) to SpeI (95683). The resulting  plasmid (pBS:E3B) was 
digested with EcoRI and XbaI to release full-length coding region 
of EBNA 3B and ligated to the Sinai site of PSC11. 
All constructs had the potential to encode the relevant fulMength 
EBV protein except for EBNA 2 deletion mutants.  The diagram- 
matic representation ofEBNA 2 deletion mutants is shown in Fig. 
1. All constructs  utilize the authentic  start and stop codons. All 
constructs  are under the control of vaccinia virus P7.5 promotor, 
except EBNA 1, which has been described elsewhere (19). A vac- 
cinia virus construct made from insertion of the pSC11 vector alone 
and negative for thymidine kinase (Vacc.TK-) was used as control. 
Source of Generation of EBV-specific CTL  Clones.  UM  cells 
(106/ml) from each donor were cultivated with irradiated (8,000 
tad) autologous type I (B95.8) LCLs (responder to stimulator ratio 
of 200:1) in 2-ml culture wells (Linbro Chemical Co., Ham&n, 
CT) for 3 d in growth medium. In the case of donors LC and IM, 
CTL clones were also established after stimulation  with BL74- 
transformed autologous I.CLs. CTL dones generated by seeding 
in 0.35% agarose were established from these donors and main- 
tained as described earlier (9, 11). Colonies were harvested after 
3 d and amplified in culture with biweekly restimulation with rlL-2 
and autologous  I.CL. 
Cytotoxicity Assay on LCLs.  CTL clones from each donor were 
screened in a standard 5-h SlCr release assay (at an E/T ratio  of 
5:1 or 10:1) for specific reactivity against autologous types 1 and 
2 and allogeneic type 1 I.CLs as previously described (11). Clones 
were designated as being EBV-specific  on the basis of recognition 
of the autologous  type 1 LCL and lack of recognition  of MHC- 
unrelated LCLs and autologous  anti-/~ B cell blasts and/or PHA 
bhsts. 
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Anti-# B cell bhsts or type 2 LCLs were infected with recombinant 
vaccinia viruses at a muhiplicity of infection (M.O.I.) of 10:1 for 
1 h at 37~  as described  earlier (14). After 14-16 h, ceils  were washed 
with RPMI 1640 and incubated with SlCr for 90 min, washed 
three times, and used as targets in a standard 5-h StCr-release  assay 
as described above. The effector cells were added to the assay at  LC 
E/T ratios between 5:1 and 10:1. To confirm the expression of  EBV  IM 
antigens in anti-# B call blasts and/or LCLs after recombinant vac-  DM 
cinia infection, the infected cells were also processed for immuno-  CM 
blotting and immunofluorescence (14).  PM 
Screening of CTL Clones  for Peptide Epitope Specificity.  To iden- 
tify the CTL epitopes recognized by EBV-specific  CTL clones from  AS 
each donor, a series of peptides from EBNA or LMP 1 were syn-  NB 
thesized (10-15 amino acids) (20) based on the known sequence  DD 
of the B95.8 strain of EBV. Peptides selected were primarily based  LX 
on the results of recombinant vaccinia CTL assays and those that 
corresponded to predicted algorithms (21, 22). Peptides were dis-  LL 
solved in ILPMI 1640 and distributed into U-bottomed microdilu-  CS 
tion plates (200/~g/ml, 20/zl/well) and frozen at  -70~  until  SJ 
required. SlCr-labeled anti-/~ B cell blasts were added to each well  JA 
(2  x  10Vml, 50/A/ml) and incubated at 37~  After 1 h, 130 
#1 of cloned autologous CTLs were added to the reaction mixture  JS 
(final E/T ratio as indicated), and the assay was conducted as de- 
scribed above. 
Results 
Localization of  EBV CTL Epitopes in EBViraraune Donors.  A 
total of 362 clones were isolated from a panel of 14 healthy 
EBV-immune donors after stimulation with irradiated autol- 
ogous B95.8- or BL74-transformed LCLs. Of these, 212 were 
EBV-spedfic CTLs. The proportion of these specific CTL 
clones from each donor varied from 100% (17/17 for donor 
DM) to as low as 16%  (8/51 for donor AS) (Table 2). 
To define the antigen specificity of the 212 EBV-spedfic 
CTL clones, autologous anti-# B cell blasts or type 2 LCLs 
were infected with recombinant vaccim'a  expressing individual 
EBV latent antigens (and Vacc.TK-) and used as targets in 
a StCr release assay. The reactivity of five EBV-specific  clones 
from one of the 14 donors (DD) is illustrated in Fig. 2, and 
demonstrates that two of these clones recognize Vacc.EBNA 
3A (CTL5 and CTL13), two recognize Vacc.LPM1 (CTL8 
and CTL10), while the antigen specificity of one done (CrL9) 
was not defined by the panel of vaccinia constructs. Table 
Table  1.  HLA Antigen (Class I) Type of the EBV-immune 
Donors Included in this Study 
Donor  HLA typing 
A1,  B8, B18 
A1,  All, B8, B51 
A24,  A29, B44, B47 
All,  A24,  B7, B44 
All,  A29,  B7, B44 
A2,  A24,  B51, B62 
A2,  A24, B7, B35 
A1,  A3,  B8, B40 
A24,  B15, B38 
A2,  B7, B44 
A2,  A23, B35, B44 
A2,  A3,  B7, B44 
A2,  All,  B7, B15 
A1,  A2,  B8, B51 
2 presents a summary of the EBNA/LMP 1 vaccinia con- 
structs recognized by CTL clones from each of the 14 donors. 
All vaccinia constructs except Vacc.EBNA 1 and Vacc.EBNA 
3B were recognized by EBV-specific CTL clones. However, 
it should be emphasized that recognition of Vacc.EBNA 3B-in- 
fected anti-# B cell blasts by EBV-specific CTL clones was 
assessed in only five donors (Table 2). A dominant response 
through a single vaccinia construct was observed with some 
donors (DM, CM, and CS recognized primarily Vacc.EBNA 
3C) (Table 2). An important feature of these results was that 
the majority (145/212) of EBV specific clones failed to recog- 
nize any of the latent antigens encoded by vaccinia constructs 
(Table 2). This was particularly evident in the case of donors 
PM and JA, where none of the clones recognized cells in- 
fected with any of the vaccinia constructs. 
MHC  Class  I  Restriction of Vaccinia-localized CTL  Epi- 
topes.  Of the 212 EBV-specific CTL clones investigated in 
the present study, 20 distinct epitopes were localized using 
vaccinia constructs. CTL clones specific for seven of these 
epitopes were type 1 specific, while clones specific for nine 
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Figure  1.  Diagrammatic representation of  B95.8 
EBNA 2 sequence and of vacdnia constructs encoding 
EBNA 2 and its deletion  mutants. The construct  encoding 
the fuU-length EBNA 2 is designated (m), while the 
regions deleted from EBNA 2 are designated (V]). De- 
tails for the preparation of these mutants has been pub- 
lished earlier (15). Each recombinant  vaccinia  had the ca- 
pacity to encode truncated EBNA 2 proteins with the 
following  amino  acid  residues  deleted:  Vacc.HB  has amino 
acid residues 19-118 deleted; Vacc.BB has amino acid 
residues 151-327 deleted;  Vacc.St  has amino acid  residues 
203-237 deleted; Vacc.Sp  has amino acid  residues 251-384 
deleted; and Vacc.PP has amino acid residues 405-480 
deleted. 
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No.  of  EBV  Vacc.  Vacc.  Vacc.  Vacc.  Vacc.  Vacc.  Vacc. 
Donor  clones  specific  dones*  EBNA  1  EBNA  2s  EBNA  3A  EBNA  3B  EBNA  3C  EBNA  LP  LMP  1 
LC  47  44  -if  2  7  -  -  -  1 
IM  26  15  -  -  4  -  -  - 
DM  17  17  -  -  -  NT I  12  -  - 
CM  29  19  -  -  1  NT  6  -  - 
PM  25  17  -  -  NT  -  -  - 
AS  51  8  -  -  1  NT  -  -  3 
NB  42  8  -  5  1  NT  -  1  1 
DD  21  17  -  -  3  -  -  -  3 
LX  14  5  -  -  3  .... 
LL  19  16  -  1  NT  2  2  1 
CS  15  12  -  -  -  NT  4  -  - 
sJ  24  19  -  -  1  NT  -  -  - 
JA  12  4  -  -  -  NT  -  -  - 
JS  20  11  -  2  ..... 
Total  362  212  0  9  22  0  24  3  9 
* Total  number of clones tested  for cytolytic  activity. 
This  column summarizes the number of EBV-specific  CTL  clones isolated  from each  individual  donor. 
S This column refers to  the number of clones recognizing autologous  anti-#  B  cell blasts infected with  recombinant vaccinia  encoding EBNA  2. 
II No clones reactive  to  vaccinia  construct. 
I Not  tested. 
other epitopes recognized both type 1 and type 2 transfor- 
mants. The type specificity of four epitopes was undefined 
(Table 3). The HLA restriction of the specific epitopes was 
determined by comparing the lysis of autologous LCLs and 
allogeneic LCLs sharing one or more alleles (Table 3). CTL 
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Figure 2.  Specific lysis by EBV-specific CTL clones (CTL5,  8,  9,  10, 
and 13) from donor DD of autologous I.CLs (DD/B95.8) and Vacc. EBNA 
1, 2, 3A, 313, 3C, LP, LMP 1, and TK- -infected DD anti-/~ B cell blasts. 
Anti-/~ B cell blasts were infected for 12-14 h (M.O.I., 10:1) with vaccinia 
constructs and processed for standard slCr release assay.  Vacc.TK-  was 
used as a control recombinant vaccinia.  Results are expressed as percent 
specific lysis observed in a standard 5-h chromium-release assay.  An E/T 
ratio of 5:1  was used throughout the assay. 
clones restricted through eight different alleles were observed 
while the restricting alleles for five EBV CTL epitopes were 
undetermined (Table 3). An important feature of these results 
was that different clones restricted through HLA A2, B7, 
B40, B8, and B51 each recognized epitopes included in two 
different latent antigens (Table 3). This observation implies 
that a single allele can present two distinct EBV CTL epitopes. 
More precise localization of CTL epitopes within EBNA 
2 was facilitated by the availability of deletion mutants en- 
coding truncated EBNA  2  proteins.  In  all,  nine EBNA 
2-specific  CTL clones restricted through three different al- 
leles (HLA A2, B18, and B7) were isolated (Table 3).  The 
A2-restricted clones from donors JS and NB recognized four 
deletion mutants (Vacc.BB, Vacc.St, Vacc.PP and Vacc.Sp) with 
a level of lysis comparable with Vacc.EBNA 2. In contrast, 
the Vacc.HB mutant,  which had a deletion affecting  the 
NH2 terminus of EBNA 2 protein (Fig.  1), was not recog- 
nized by these clones. Data from one such A2-restricted CTL 
clone from donor NB is shown in Fig. 3 a. In contrast, the 
HLA B18-restricted EBNA 2-specific CTL clones (from 
donor LC), failed to recognize Vacc.Sp and Vacc.BB deletion 
mutants, which had overlapping deletions for amino acids 
251-327 of EBNA 2 protein (Figs.  1 and 3 b). 
Based on the results obtained from the vaccinia experiments, 
EBV peptides from respective EBNA/LMP 1 regions were 
screened for their ability to sensitize autologous anti-/~ B cell 
blasts for EBV-specific CTL lysis. In some instances, this in- 
volved the selection of 15-20-mer peptides from individual 
172  EBV CTL  Epitopes Recognized  by Human CTL  Clones Table 3.  Summary of the Distribution of MHC Class 1-restricted EBV CTL Peptide Epitopes within EBV Latent Antigens Localized 
by Recombinant Vaccinia 
EBV antigen  HLA  EBV  type 
recognized  restriction  Peptide epitope  specificity  Donor(s) 
EBNA 2  HLA A2  DTPLIPLTIF  ~  Type 1  JS and NB 
EBNA 2  HLA B18  PRSPTVFYNIPPMPL~  Type 1  LC 
EBNA 2  HLA B7  Undefined  Type 1 and 2  NB 
EBNA 3A  HLA B8  FLRGRAYGLS  Type 1  LC and IM 
EBNA 3A  HLA B7  Undefined  Type 1 and 2  NB and SJ 
EBNA 3A  HLA All  or A24  Undefined  Type 1  CM 
EBNA 3A  HLA B51  Undefined  Type 1  AS 
EBNA 3A  Undefined  Undefined  ND  LX 
EBNA 3A  HLA 40  Undefined  ND  DD 
EBNA 3A  Undefined  Undefined  Type 1 and 2  LL 
EBNA 3C  HLA A24 or B44  RGIKEHVIQNAFRKA*  Type 1  CM and DM 
EBNA 3C  HLA B44  EENLLDFVRFII  Type 1 and 2  DM,  CM, CS, and LL 
EBNA 3C  Undefined  Undefined  Type 1 and 2  CS 
EBNA LP  Undefined  Undefined  Type 1 and 2  NB and LL 
LMP 1  HLA A2  Undefined  Type 1 and 2  LL and NB 
LMP 1  HLA B51  Undefined  Type 1 and 2  AS 
LMP 1  HLA B40  Undefined  ND  DD 
LMP 1  HLA A24  Undefined  Type 1 and 2  AS 
LMP 1  Undefined  Undefined  Type 1  LC 
LMP 1  HLA B8  Undefined  ND  DD 
" Reference 23. 
* This study. 
$ Reference 12. 
It Reference 13. 
latent  antigens  that  corresponded  to predicted  algorithms 
(20-22).  However, to define epitopes from EBNA 2, pep- 
tides were selected that corresponded to the relevant vaccinia 
deletion mutant.  Of the 20 distinct CTL epitopes localized 
in this study, five were defined at the peptide level while the 
other 15 remained undefined (Table 3). Of these five epitopes, 
three have been previously published (12, 13, 23), while new 
epitopes from EBNA 2 and EBNA 3C are presented in Table 
3. The results of experiments that define these new epitopes 
are included in Fig. 4, a and b. The HLA B18-restricted EBNA 
2-specific clone recognized autologous anti-#  B cell blasts 
sensitized  with  peptide  PRsgrVFYNIPPMPL  (residue 
number 276-290),  while the EBNA 3C-specific done, re- 
stricted through either HLA A24 or B44, recognized pep- 
tide RGIKEHVIQNAFRKA (residue number 332-346) (Fig. 
4,  a  and  b). 
Discussion 
There is convincing evidence that  EBV-specific  memory 
T cells are responsible for controlling the level of EBV-positive 
B lymphocytes, which all healthy seropositive individuals  carry 
for life after primary infection with the virus. Experimental 
support for the existence of this protective memory T  cell 
population came from the observation that in virus-infected 
cultures of mononudear lymphocytes from seropositive (but 
not seronegative) donors, the initial proliferation of EBNA- 
positive B calls was followed by a complete T cell-dependent 
regression of growth such that LCLs could not be established 
from subcultures (24, 25). This observation suggested that 
the latent  antigens expressed by these LCLs were a source 
of target  antigens.  Indeed,  we have recently demonstrated 
the existence of CTL epitopes within  three of the EBNA 
proteins by screening individual clones against a pand of pep- 
tides derived from a range of latent antigens. Although these 
studies identifed several CTL epitopes (12, 13, 23), there has 
been no previous attempt to determine the relative distribu- 
tion of CTL epitopes within EBV proteins,  recognized by 
healthy immune donors expressing an array of MHC class 
I alldes. Such an evaluation is a mandatory prerequisite for 
any future CTDbased vaccine to EBV. The present study pro- 
vides an extensive analysis  of the distribution  of CTL epi- 
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Figure 3.  Functional  analysis of EBNA 2-specific  CTL clones from 
donors  NB (a) and IX] (b) generated  from an in vitro stimulation with 
autologous  B95.8 LCLs and tested on autologous  type 1 LCL (NB/B95.8 
or LC/B95.8) and anti-# B cell blasts infected with recombinant  vaccinia 
carrying EBNA 2 gene deletions (Vacc.HB, BB, St, PP, and Sp), Vacc.EBNA 
2,  or Vacc.TK-. Results  are expressed as in Fig.  2.  For details on the 
amino acids deleted from each recombinant  vaccinia, see legend to Fig. 1. 
topes within viral-encoded proteins. Using recombinant vac- 
cinia  encoding  individual  EBV  latent  antigens,  we  have 
successfuUy localized target epitopes recognized by CTL clones 
from a panel of EBV-immune donors. 
The location of CTL epitopes within the seven latent an- 
tigens, for which vaccinia constructs were available,  was un- 
evenly distributed. In particular, EBNA 3A and EBNA 3C 
were common sites for CTL recognition (11/14 donors had 
CTL reactivity to either of these antigens), while no epi- 
topes were localized in EBNA  1 and EBNA 36.  Since, in 
the present study, Vacc.EBNA 3B was not available  to test 
the reactivity of CTL clones from nine donors, it is not pos- 
sible to draw any conclusions about the occurrence of epi- 
topes in this protein. The immunodominance of the EBNA 
3 family of proteins as a source of EBV CTL epitopes seen 
in  this  study  using  EBV-specific  CTL  clones  has  been 
confirmed in a similar study using polyclonal EBV-specific 
T  cdls (19).  In all,  20 distinct CTL specificities restricted 
through  eight  different  class  I  alleles  have been  defined. 
Interestingly, HLA A2, B7, 68, B40, and B51 alhles were 
each shown to present two distinct CTL epitopes derived 
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Recognition of peptide-sensitized  autologous  anti-~ B cell 
blasts by EBV-specific  CTL clones from donors IX: (a) and CM (b). slCr- 
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and subsequently  screened in a CTL assay using the relevant CTL clone. 
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from different latent antigens. The ability of single MHC 
alleles to present multiple epitopes has also been reported with 
HIV (26). 
Surprisingly, the specifidty of a large number of EBV-specific 
CTL clones (68%) using the available panel of vaccinia con- 
structs could not be defined. A possible explanation for this 
result is that the undefined epitopes are located within EBV 
latent antigens other than those encoded by the vaccinia con- 
structs available  for this study; for example, terminal pro- 
teins (TP 1 and TP 2), LMP 2, or as yet unidentified latent 
antigens.  Alternatively,  antigens associated with  the EBV 
replicative cycle could also indude CTL epitopes. These an- 
tigens are detected in only a small proportion of latently in- 
fected cells by conventional techniques. However, the exqui- 
site sensitivity by which CTLs recognize peptide fragments 
(27) from viral antigen raises the possibility that low levels 
of replicative antigens could be processed and presented as 
target epitopes on LCLs. It is relevant to point out that in 
another related study, EBNA 3B and LMP 2 were identified 
as targets for EBV-specific  recognition (19).  These observa- 
tions suggest that all latent antigens except EBNA 1 are targets 
for EBV-speciflc CTL recognition, although a disproportionate 
number of CTL epitopes are located within the EBNA 3 
proteins. 
174  EBV CTL Epitopes  Recognized by Human CTL Clones There are two important implications for the overall bi- 
ology of EBV if subsequent studies confirm that EBNA 1 
does not include CTL epitopes. First, the ability of BL cells 
(which express only EBNA 1) to proliferate in vivo, in spite 
of a typically normal EBV-specific CTL response (28), is con- 
sistent with the observation that there are no CTL epitopes 
within EBNA 1. In vitro studies have indicated that BL cells 
are much less susceptible to EBV-spedfic CTL lysis than LCLs 
from the same donor (29).  Down-regulation of HLA class 
I alleles (30) and adhesion molecules (e.g., LFA-1 and -3, and 
ICAM-1) (31) have been implicated as possible mechanisms 
for this resistance of BL cells to lysis. However, recent obser- 
vations  from this  laboratory using peptide  epitopes from 
EBNA 2, 3A, and 3C have demonstrated that downregnla- 
tion of latent antigen expression is the most critical factor 
in the nonrecognition of BL cells (Khanna et al., manuscript 
in preparation). 
The lack of detectable CTL epitopes within EBNA 1 has 
a second important implication in regard to the persistence 
of EBV in peripheral B cells. A model for the persistence of 
EBV in B cells has recently been proposed. A feature of this 
model is the existence of a long-lived, non-replicating, EBNA 
1-expressing B cell (32). The observations from the present 
study provide a mechanism by which these cells can main- 
tain a nonimmunogenic phenotype by not expressing the crit- 
ical latent proteins needed for CTL recognition. 
Of the 20 CTL epitopes localized by recombinant vaccinia, 
five were defined at the peptide level.  In addition to three 
previously published epitopes (12, 13, 23), in the present study 
we have defined two new epitopes, one in EBNA 2 and one 
in EBNA 3C.  Although CTL clones specific for nine epi- 
topes recognized both type 1 and type 2 transformants, a 
significant number of epitopes (7/16 epitopes for which EBV 
type was determined) were specific for type 1 EBV. Since we 
have recently shown that the majority of single amino acid 
substitutions within CTL epitopes result in loss of recogni- 
tion (33), the common isolation of type 1-specific CTL clones 
is not unexpected when the degree of latent antigen sequence 
variation between the two types is compared (7). 
The present study has important implications for any fu- 
ture EBV vaccine designed to control IM or EBV-associated 
tumors. First, CTL epitopes from a spectrum of individuals 
are distributed throughout most of the latent proteins. Second, 
>60%  of the CTL epitopes are located in regions outside 
the EBNA/LMP 1 proteins. Both of these considerations sug- 
gest that any EBV vaccine based on CTL epitopes designed 
to provide widespread protection will need to include not 
only EBNA and LMP sequences but also other regions of 
the genome expressed during latent infection. However, since 
CTLs from the majority of donors recognized EBNA 3A 
and EBNA 3C as target antigens, incorporation of epitopes 
derived from these proteins into a vaccine may protect the 
majority of susceptible individuals from IM. The inability 
of human CTLs to recognize EBNA 1 as a target antigen, 
often the only latent antigen expressed in BL and NPC, sug- 
gests that CTL control of these tumors will not be feasible 
unless the downregulation of latent antigens can be reversed. 
The localization of CTL epitopes within LMP, however, raises 
the possibility of controlling EBV-associated  tumors with 
normal LMP expression (Hodgkin's lymphoma and some 
NPC) by boosting the CTL response to this antigen. 
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